Indrayani Biotech Director Resigns; Board to Review on March 24

Indrayani Biotech Limited has announced that its Whole-time Director, Mr. Singarababu Indirakumar, has resigned. He submitted his resignation on March 16, 2026, and the company officially received it on March 19. The company's Board of Directors is scheduled to meet on March 24, 2026, to formally consider and accept his departure. This development comes as the diversified company navigates a period of operational challenges and management shifts.

Mr. Indirakumar's role as a Whole-time Director was critical for the company's day-to-day operations and strategic execution. His resignation may signal shifts in management dynamics or ongoing restructuring efforts for Indrayani Biotech, which operates across a broad spectrum of industries including food and hospitality, dairy, healthcare, pharmaceuticals, engineering, biotechnology, agriculture, and infrastructure. The company has integrated and acquired various businesses particularly since 2018.

The company has faced recent financial and compliance issues. In December 2025, Indrayani Biotech was fined by the BSE for late submission of financial results. In January 2026, it received a demand notice regarding a defaulted term loan. Past financial analyses have also pointed to high debtor days (165 days) and increasing working capital days, suggesting potential operational inefficiencies. Notably, Mr. Indirakumar is also slated for retirement by rotation at the company's upcoming Annual General Meeting.

Financially, Indrayani Biotech reported a 37.39% decrease in annual revenue to ₹41.29 crore for the fiscal year 2025, down from ₹65.94 crore in FY 2024 (standalone). Annual net profit saw a slight decrease of 0.76%, falling to ₹1.45 crore in FY 2025 from ₹1.46 crore in FY 2024.

Following the board's decision on March 24, 2026, the company will have a vacancy in the Whole-time Director position. Investors will be looking for clarity on the company's strategy for managing this transition, including potential interim arrangements or the search for a new director. The company's ongoing regulatory scrutiny and financial strain remain key areas of focus.

Direct peer comparison for Indrayani Biotech is difficult due to its diversified nature. However, in its agri-business segments, companies like L T Foods Ltd, KRBL Ltd, Kaveri Seed Co. Ltd, and TruAlt Bioenergy Ltd operate in related sectors.

Investors will be tracking the outcome of the March 24 board meeting, any announcements on management changes, and future financial updates to understand the company's strategic direction.